dc.contributor |
Landspitali - The National University Hospital of Iceland |
dc.contributor.author |
TraP Hep C group |
dc.date.accessioned |
2022-08-18T01:03:05Z |
dc.date.available |
2022-08-18T01:03:05Z |
dc.date.issued |
2022-04-19 |
dc.identifier.citation |
TraP Hep C group 2022 , ' High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program-A Prospective Nationwide, Population-Based Study ' , Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , vol. 75 , no. 10 , pp. 1732-1739 . https://doi.org/10.1093/cid/ciac272 |
dc.identifier.issn |
1058-4838 |
dc.identifier.other |
56721899 |
dc.identifier.other |
ec874dc5-0e3b-4cd8-95fc-2cbbc709152c |
dc.identifier.other |
35438144 |
dc.identifier.other |
unpaywall: 10.1093/cid/ciac272 |
dc.identifier.other |
85141934363 |
dc.identifier.uri |
https://hdl.handle.net/20.500.11815/3327 |
dc.description |
Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. |
dc.description.abstract |
BACKGROUND: The Treatment as Prevention for Hepatitis C program started in 2016 in Iceland, offering treatment with direct-acting antivirals to hepatitis C virus (HCV)-infected individuals. Reinfections through injection drug use (IDU) can hamper elimination efforts. We determined reinfection rates of HCV among patients in the program. METHODS: Clinical data were gathered prospectively. The study cohort consisted of HCV-cured patients with an estimated sustained virologic response between 1 February 2016 and 20 November 2018, with follow-up until 20 November 2019. The observation period and time until reinfection was estimated using a single random point imputation method coupled with Monte Carlo simulation. The reinfection rates were expressed as reinfections per 100 person-years (PY). RESULTS: In total, 640 treatments of 614 patients (417 male; mean age, 44.3 years) resulted in cure, with 52 reinfections subsequently confirmed in 50 patients (37 male). Follow-up was 672.1 PY, with a median time to reinfection of 232 days. History of IDU was reported by 523 patients (84.8%) and recent IDU with 220 treatments (34.4%). Stimulants were the preferred injected drug in 85.5% of patients with a history of IDU. The reinfection rate was 7.7/100 PY. Using multivariate Cox proportional hazards models for interval-censored data, age (hazard ratio, 0.96 [95% confidence interval, .94-.99]) and recent IDU (2.91 [1.48-5.76]) were significantly associated with reinfection risk. CONCLUSIONS: The reinfection rate is high in a setting of widespread stimulant use, particularly in young people with recent IDU. Regular follow-up is important among high-risk populations to diagnose reinfections early and reduce transmission. CLINICAL TRIALS REGISTRATION: NCT02647879. |
dc.format.extent |
8 |
dc.format.extent |
488910 |
dc.format.extent |
1732-1739 |
dc.language.iso |
en |
dc.relation.ispartofseries |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America; 75(10) |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Meltingarlæknisfræði |
dc.subject |
Veirufræði |
dc.subject |
Vísindadeild |
dc.subject |
Lifrarbólga C |
dc.subject |
Smitsjúkdómalæknisfræði |
dc.subject |
harm reduction |
dc.subject |
hepatitis C |
dc.subject |
injection drug use |
dc.subject |
reinfection |
dc.subject |
treatment program |
dc.subject |
Recurrence |
dc.subject |
Prospective Studies |
dc.subject |
Humans |
dc.subject |
Substance Abuse, Intravenous/complications |
dc.subject |
Male |
dc.subject |
Reinfection |
dc.subject |
Drug Users |
dc.subject |
Incidence |
dc.subject |
Hepatitis C/drug therapy |
dc.subject |
Antiviral Agents/therapeutic use |
dc.subject |
Adolescent |
dc.subject |
Adult |
dc.subject |
Hepatitis C, Chronic/drug therapy |
dc.subject |
Hepacivirus |
dc.subject |
Microbiology (medical) |
dc.subject |
Infectious Diseases |
dc.title |
High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: : Results From the TraP Hep C Program-A Prospective Nationwide, Population-Based Study |
dc.type |
/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article |
dc.description.version |
Peer reviewed |
dc.identifier.doi |
10.1093/cid/ciac272 |
dc.relation.url |
http://www.scopus.com/inward/record.url?scp=85141934363&partnerID=8YFLogxK |
dc.contributor.department |
Faculty of Medicine |
dc.contributor.department |
Other departments |
dc.contributor.department |
Clinical Laboratory Services, Diagnostics and Blood Bank |
dc.contributor.department |
Faculty of Life and Environmental Sciences |
dc.contributor.department |
Internal Medicine and Emergency Services |